Protomer Technologies Completes New Funding

Protomer Technologies("Protomer"), the biopharmaceutical company, today announces the completion of an investment by the JDRF T1D Fund following an initial equity investment in Protomer led by Eli Lilly and Company.

Protomer is engineering next-generation protein therapeutics that can sense molecular activators in the body. The company's proprietary Molecular Engineering of Protein Sensors (MEPS) platform enables the development of therapeutic peptides and proteins with tunable activity that can be controlled using small molecules. Protomer has used this approach toward developing a portfolio of therapeutic candidates, including a glucose responsive insulin that can sense sugar levels in the blood and automatically activate as needed throughout the day. Protomer's chemical biology-based MEPS platform enables rapid turn-on and turn-off capability for automatic activity control of peptides and proteins. This technology will enable development of targeted therapies with dual homing to reduce off-target effects.